UPDATE: UCB's drug candidate for lupus fails Phase III trial
Belgian drugmaker UCB (Euronext Brussels: UCB) on Tuesday said its drug candidate for chronic autoimmune disease lupus, did not meet efficacy endpoints in Phase IIII trials. The company in a statement said the two Embody Phase III clinical studies for epratuzumab in systemic lupus erythematosus (SLE) did not meet their primary clinical efficacy endpoints in either dose in both studies.
UCB said the treatment response in patients who received epratuzumab in addition to standard therapy was not statistically significantly higher than those who received placebo in addition to standard therapy. The company's shares fell 3.5% to 67.08 euros on the disappointing news.
Iris Loew-Friedrich, chief medical officer and executive vice president, UCB said: “Today’s news does not alter UCB’s strategy as we remain committed to delivering value for patients living with lupus and other immunologic diseases.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze